Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness
PRESS RELEASE
Beacon Therapeutics launches with £96 million ($120 million) to develop a new generation of gene therapies for retinal diseases resulting in blindness
- New leading gene therapy company created combining late-stage X-linked retinitis pigmentosa (XLRP) program from AGTC, a preclinical program spun out from the University of Oxford and a second preclinical program to deliver a broad ophthalmic development pipeline
- Led by a highly experienced leadership team including David Fellows, Dr. Nadia Waheed, and Dr. Abraham Scaria, each with decades of ophthalmic gene therapy experience
- £96m ($120 million) in funding from lead investor Syncona and additional investors including Oxford Science Enterprises (OSE) to progress pipeline to key value inflection points
London and Oxford, UK, 12 June 2023 – Beacon Therapeutics Holdings Limited (‘Beacon Therapeutics’ or ‘the Company’), a leading ophthalmic gene therapy company with a purpose to restore and improve the vision of patients with retinal diseases, launches today and will develop a new generation of gene therapies to treat a range of rare and prevalent retinal diseases that result in blindness. Syncona Limited, with additional investors including OSE, has provided £96 million ($120 million) to fund the acquisition of AGTC and provide capital to take each of Beacon Therapeutics’s development candidates through to value inflection points.
Beacon Therapeutics’s lead clinical asset is AGTC-501, a gene therapy program currently in Phase II clinical trials for the treatment of XLRP that was acquired as part of Syncona’s acquisition of AGTC in November 2022. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. Unlike other approaches in the space, AGTC-501 correctly expresses the full length RPGR protein, thereby addressing the entirety of photoreceptor damage caused by XLRP, including both rod and cone loss.
Beacon Therapeutics’s first pre-clinical asset is an intravitreally (IVT) delivered novel AAV based program for dry Age-related Macular Degeneration (dry AMD). Dry AMD is a leading cause of irreversible vision loss in people over 60, if left untreated. Around 20 million people in the United States suffer from AMD.
The second pre-clinical asset is targeting cone-rod dystrophy (CRD) which is caused by a null mutation in the Cadherin Related Family Member 1 (CDHR1) gene. The program has been licensed from the laboratory of Professor Robert MacLaren, Professor of Ophthalmology at the University of Oxford. Prof. MacLaren, a world leading retinal expert and an experienced biotech company founder and a Co-Founder of Beacon Therapeutics, will become a key scientific advisor to the company and will join the board of directors.
To bolster its pipeline in the future, Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space.
Beacon Therapeutics will be led by David Fellows, the former Chief Executive of Nightstar Therapeutics with over 40 years’ experience in the ophthalmology field. He will be joined by retinal expert Dr. Nadia Waheed as Chief Medical Officer, formerly from Gyroscope Therapeutics. Dr. Abraham Scaria also joins the team from AGTC as Chief Scientific Officer bringing 25 years of experience in gene therapy, ranging from discovery research to early-stage clinical trials.
David Fellows, Chief Executive Officer of Beacon Therapeutics commented: “Beacon Therapeutics combines a broad development pipeline, a deep scientific foundation, a strong clinical network, and a highly experienced management team to drive forward a unique late-stage clinical and pre-clinical pipeline. With the 12-month data from our Phase II SKYLINE trial for AGTC-501 expected shortly and two highly innovative and differentiated pipeline assets for prevalent and rare blinding diseases, we are excited to be building a new leader in the ophthalmic gene therapy space.”
Chris Hollowood, CEO of Syncona Limited, the lead investor in Beacon Therapeutics commented: “By acquiring AGTC and combining its late-stage program with highly complementary and innovative science from the University of Oxford and elsewhere, we have created an exciting new gene therapy company in an area where we have a great breadth and depth of knowledge and expertise. We look forward to working closely with Beacon Therapeutics’ exceptional management team to advance these assets through the clinic and towards people suffering from debilitating retinal diseases.”
Professor Robert MacLaren, Professor of Ophthalmology, University of Oxford, and Co-Founder of Beacon Therapeutics commented: “I have dedicated many years to translating pioneering gene therapies from the lab through to clinical trial phase with the support of my team in the Nuffield Laboratory of Ophthalmology and NIHR Oxford Biomedical Research Centre (BRC). Beacon Therapeutics is quite unique in being a company that at launch is already underpinned by excellent clinical trial data. The company has both highly innovative retinal gene therapy programmes and the means to target them to the main causes of blindness in both the young and old.”
Katya Smirnyagina, Senior Partner, Life Sciences, Oxford Science Enterprises (OSE) added: “Beacon Therapeutics is truly an exciting new company built around an established scientific foundation and a wealth of experience in the gene therapy and ophthalmology space. We are delighted that expertise spun out from the University of Oxford will become a key component to drive the future success of the business that could bring significant change in the treatment of a broad range of retinal diseases that cause blindness.”
Broad ophthalmic development pipeline
The company’s lead clinical gene therapy program AGTC-501 has a strong body of clinical evidence targeting XLRP, an inherited rare form of retinitis pigmentosa that causes progressive vision loss in boys and young men. AGTC-501 demonstrated meaningful efficacy and a good safety profile in the recent Phase I/II HORIZON trial and expects to be publishing 12-month data from its Phase II SKYLINE trial in the second half of 2023. In addition, Beacon Therapeutics is awaiting feedback from the US Food and Drug Administration (FDA) regarding the study design of its upcoming VISTA clinical trial, a Phase II/III study to assess the effect of AGTC-501 on the symptoms of retinitis pigmentosa in additional patients with XLRP.
The first preclinical program features intravitreally (IVT) delivered gene therapy for dry AMD. IVT delivery provides access to a significantly greater number of patients than sub-retinal delivery as it can be administered within an outpatient clinic rather than requiring surgery.
The second preclinical program, CRD, targets mutations in the CDHR1 gene, which may cause central vision loss similar to dry AMD in older people and severe sight loss in younger patients.
The Company has a new location in London, UK, complementing existing facilities in Boston, Massachusetts and Alachua, Florida, US.
Contacts:
Beacon Therapeutics:
David Fellows, CEO
Email: info@beacontx.com
Consilium Strategic Communications:
Alex Harrison, Ashley Tapp
Email: Beacon@consilium-comms.com
Tel: +44 (0)20 3709 5700
About Beacon Therapeutics
Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another in-licensed from the University of Oxford targeting cone-rod dystrophy (CRD), an inherited retinal disease.
Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss.
Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space.
The Company is supported by funds from Syncona and additional investors including Oxford Science Enterprises.
Find out more about us online at: www.beacontx.com.
TIN LIÊN QUAN
Cellbox Solutions Raises EUR 6.5 Million in Series A1
- CK Ventures, Fraunhofer Ventures, NRW.Venture and Fil Bros join forces with renowned private investors- Planned expansion of US business and launch of...
Beam Therapeutics to Participate in the 43rd Annual Cowen
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic...
Sana Biotechnology Announces the Acceptance of Four
Late-breaking poster presentation to highlight preclinical data demonstrating that the increased potency of CD8-targeted fusosomes enhances CAR gene...
THỦ THUẬT HAY
Cách khắc phục khi Facebook của bạn bị 'dính' Virus
Nếu Facebook bị virus hoặc tài khoản của bạn đã bị hack? Dưới đây là bốn cách mà bạn nên thử: phục hồi tài khoản của bạn, thay đổi mật khẩu của bạn, loại bỏ các ứng dụng nghi ngờ, và thực hiện quét virus.
Đem tính năng bảo mật độc quyền của Galaxy A 2017 lên mọi máy Android
Bộ đôi Samsung A5 2017 và A7 2017 được trang bị tính năng bảo mật SecureFolder, xuất hiện lần đầu tiên trên siêu phẩm Galaxy Note 7. Đây là cách bạn mang tính năng độc đáo này lên tất cả các máy Android khác dễ dàng.
Cách tạo hình ảnh động với hiệu ứng đặc biệt chỉ với iOS 11 và Live Photo
Bản cập nhật iOS 11 mang lại khá nhiều thay đổi trong giao diện cũng như thêm các tính năng hay. Bài viết này sẽ hướng dẫn bạn tạo ra những bức...
Muốn chống theo dõi vị trí điện thoại, tắt định vị GPS là chưa đủ
Sở hữu một chiếc smartphone hiện đại sẽ mang lại nhiều tiện ích hữu dụng cho người dùng tuy nhiên cũng ẩn chứa không ít rủi ro. Một trong số đó là việc bị theo dõi vị trí bí mật. Hôm nay chúng tôi sẽ chia sẻ cho các
Cách sửa lỗi Adobe Flash Player bị chặn trên Cốc Cốc và Firefox
Không hiển thị nội dung Flash, Plugin không hồi đáp hoặc bị treo là những lỗi thường xuyên xảy ra khi duyệt web, chơi game khiến người dùng vô cùng khó chịu. Vậy phải làm sao đây?
ĐÁNH GIÁ NHANH
Đánh giá chi tiết thiết kế và cấu hình của Sharp Aquos S3
Được nâng cấp lớn về thiết kế cho tương xứng hơn với giá, ngoại hình của Sharp Aquos S3 được thay thế chất liệu nhựa bằng kính cong 3D kết hợp cùng với khung kim loại, điều này làm cho chiếc máy sang trọng cứng cáp
So sánh tốc độ iPhone X và iPhone 7 Plus
So với iPhone X, iPhone 7 Plus không thua kém là bao nhiêu cho thấy đây vẫn là một sản phẩm đỉnh cao của Apple.
Đánh giá pin Zenfone Go và Go Plus: Quá trâu trong tầm giá
Đánh giá pin của Zenfone Go và Go Plus - 2 smartphone có giá bán cực kì hấp dẫn và thiết kế trẻ trung đang được bán tại thị trường Việt Nam